What is Acid Reflux

Treatment with proton pump inhibitors (PPIs) for eight weeks induces acid-related symptoms like heartburn, acid regurgitation and dyspepsia once treatment is withdrawn in healthy individuals, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

There is minimal data evaluating the prevalence of GERD complications in any United States general population, other than non-Hispanic whites. Presently, it is thought that such complications occur less frequently in African-Americans than in non-Hispanic whites. A research group in Jacksonville, FL investigated the prevalence of reflux esophagitis between non-Hispanic whites and African-Americans.

There is minimal data evaluating the prevalence of GERD complications in any United States general population, other than non-Hispanic whites. Presently, it is thought that such complications occur less frequently in African-Americans than in non-Hispanic whites. A research group in Jacksonville, FL investigated the prevalence of reflux esophagitis between non-Hispanic whites and African-Americans.

Metoclopramide, a drug approved in the U.S. for nausea, vomiting and heartburn poses no significant risks for the fetus according to a large cohort study published in the June 11 issue of the prestigious New England Journal of Medicine, "The Safety of Metoclopramide Use in the First Trimester of Pregnancy" (N Engl J Med 2009;360:24 June 11, 2009). According to the pediatrician and clinical pharmacologist, principal investigator Dr. Rafael Gorodischer, prof.

Canadian Light Source (CLS) staff scientist Luca Quaroni and Dr. Alan Casson, Head of the Department of Surgery at the University of Saskatchewan (U of S) used the synchrotron's infrared microscope to identify tissue afflicted with a condition known as Barrett's Esophagus from chemical fingerprints associated with the disease, which can lead to esophageal cancer. The finding is published in the June, 2009 issue of the Royal Society of Chemistry journal, The Analyst.

Adding AZD3355, a novel GABAB receptor agonist, to a proton pump inhibitor (PPI) in patients with Gastroesophageal Reflux Disease (GERD), resulted in a 35% reduction in the mean total number of reflux episodes 0-24 hours after dose, compared with placebo.[i] These data were presented at the Digestive Diseases Week annual meeting (DDW®, 30 May - 4 June, Chicago).

Patients who have gastroesophageal reflux disease (GERD) for a prolonged period have an increased risk of developing Barrett's esophagus, a pre-cancerous condition where the tissue lining the esophagus becomes damaged by stomach acid and transformed into something like the inside of the stomach. New research finds that radiofrequency ablation -- an endoscopic procedure involving targeted thermal energy -- was very successful at restoring the esophagus and reducing risk for cancer.

Researchers unveiled data during Digestive Disease Week® (DDW®) 2009 examining the potential risks associated with two commonly-used treatments, particularly among the elderly: acid suppressors and antithrombotics. DDW is the largest international gathering of physicians and researchers in the field of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

Two studies from AstraZeneca (NYSE: AZN) show that symptomatic gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks(1). NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD.

(ARA) - Nearly 19 million Americans currently live with Gastroesophageal Reflux Disease (GERD), commonly known as acid reflux disease, and suffer from painful and uncomfortable symptoms such as frequent and persistent heartburn.

Hospitalized patients who receive acid-suppressive medications such as a proton-pump inhibitor have a 30 percent increased odds of developing pneumonia while in the hospital, according to a new study.

A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress.

Galway-based medical device developer Crospon has announced a worldwide distribution deal with Dutch firm Medical Measurement Systems. MMS will distribute Crospon's award-winning product EndoFLIP, which tests for gastroesophagel reflux disease (GERD), commonly known as acid reflux.

A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress. Findings from the first multicenter trial of the procedure, called radiofrequency ablation, could mean patients have an alternative to surgery for treating Barrett's esophagus.

A procedure that uses heat generated by radio waves to treat Barrett's esophagus, a condition caused by acid reflux (severe heartburn), can eliminate signs of the potentially cancer-causing disorder and reduce the risk that the disease will progress. Findings from the first multicenter trial of the procedure, called radiofrequency ablation, could mean patients have an alternative to surgery for treating Barrett's esophagus.

ALL students learn about acid reflux

They're a popular choice for the pain of indigestion and heartburn, but, a new study shows more and more hospitals are giving acid reflux drugs to people who don't need them.

Published: Wednesday, May 27, 2009 at 5:17 a.m. Last Modified: Wednesday, May 27, 2009 at 5:17 a.m. A growing number of hospital patients are routinely given drugs to prevent acid reflux.

Hospitalized patients who receive acid-suppressive medications such as a proton-pump inhibitor have a 30 percent increased odds of developing pneumonia while in the hospital, according to a study in the May 27 issue of JAMA. With the introduction of proton-pump inhibitors, used primarily in the treatment of ulcers and gastroesophageal reflux disease, the use of acid-suppressive medications has ...

A new study has found that patients who take proton pump inhibitors to prevent acid reflux are at higher risk for pneumonia than those who do not.